The model for detecting NYHA class achieved an area under the receiver operating characteristic (AUROC) curve of 0.99 at the Yale New Haven Hospital (YNHH) site, where it was developed, and AUROCs of ...

Heart failure outcomes in patients with type 2 diabetes receiving once-weekly exenatide are affected by left ventricular ejection fraction.

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

NYHA class III/IV Dilated (ischemic or idiopathic) cardiomyopathy Sinus rhythm >/= 55 bpm QRS >/= 120 ms PR interval >/= 150 ms ...

Since most of the clinical trials of -blocking agents have been conducted in patients with heart failure NYHA functional class II/III, until recently there was limited information regarding safety ...

Factors portending the greatest risk for cardiovascular death in control patients were inflammation (baseline plasma high-sensitivity C-reactive protein ≥2 mg/L; p=0.003) and ischemic HFrEF etiology ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

Of these patients, 50% were in NYHA class III and 31% had variant ATTR-CM. The mean percent change from baseline in the serum TTR level was −89% (95% confidence interval [CI], −92 to −87 ...

In this randomized controlled trial of patients with heart failure and mildly decreased or preserved ejection fraction, ...

Choosing between Pascal and MitraClip comes down to patient anatomy, with both devices working well in most cases.

Choosing between Pascal and MitraClip comes down to patient anatomy, with both devices working well in most cases.

A new trial found that tricuspid transcatheter edge-to-edge repair (T-TEER) and optimized medical therapy (OMT) enhanced the ...